Publication | Closed Access

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

Gastrointestinal OncologyMedicinePharmacologyPathologyColorectal CancerCancer TreatmentOncologyRadiation OncologyBiweekly CetuximabCancer GrowthSecond-line Chemotherapy